Truist raised the firm’s price target on Insulet (PODD) to $390 from $365 and keeps a Buy rating on the shares. The company posted another strong beat and raise on broad Omnipod 5 strength, the analyst tells investors in a research note. The firm remains confident in Insulet’s prospects to sustain a well-above-average CAGR over the 2024-2028 period, Truist added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: